Development of personalized therapeutic cancer vaccines to effectively mobilize antitumor t-cell immunity in non-small cell lung cancer

The University of California Irvine received a $156,998 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support the development of personalized therapeutic cancer vaccines to effectively mobilize antitumor T-cell immunity in non-small cell lung cancer from September 30, 2021 through September 29, 2023. As the sub-awardee, the State of California Controllers Office will assist in the delivery of products and services to advance biomedical research solutions that can transform military and public health care through innovative medical investigations for battlefield wounds and illnesses. The funding will allow researchers to develop personalized treatments to stimulate the body's immune system to fight lung cancer, advancing the military and federal government's goals of supporting impactful medical research with real-world applications.